Clinical trials: Recurrent Cutaneous Melanoma
Melanoma (Skin), Neuroblastoma
Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors
RATIONALE: Biological therapies such as hu14.18-interleukin-2 fusion protein use different ways to stimulate the immune system and stop cancer cells from growing.
- Conditions
- Melanoma (Skin), Neuroblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00003750
- Testing
- hu14.18-IL2 fusion protein
- Where
- 59 sites in United States, Australia and 1 more
- Volunteers
- 28 people
- Sponsor
- Children's Oncology Group
Borderline Ovarian Clear Cell Tumor, Borderline Ovarian Serous Tumor
Collecting Tumor Samples From Patients With Gynecological Tumors
This laboratory study is collecting tumor tissue and blood samples from patients with gynecologic tumors. Collecting and storing samples of tumor tissue and blood from patients with cancer to study in the laboratory may help in…
- Conditions
- Borderline Ovarian Clear Cell Tumor, Borderline Ovarian Serous Tumor, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
- Trial name
- NCT00897442
- Testing
- Laboratory Biomarker Analysis
- Where
- 187 sites in United States
- Volunteers
- 275 people
- Sponsor
- Gynecologic Oncology Group
Brain and Central Nervous System Tumors, Intraocular Melanoma
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 monoclonal antibody 3F8, can find tumor cells and carry tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin)
- Trial name
- NCT00445965
- Testing
- DNA analysis, immunologic technique, pharmacological study
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Melanoma (Skin)
Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma
RATIONALE: Drugs used in chemotherapy, such as dacarbazine and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00072124
- Testing
- cisplatin, dacarbazine, conventional surgery
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer, Adult Soft Tissue Sarcoma
Vaccine Therapy in Treating Patients With Metastatic Cancer
RATIONALE: Vaccines made from a peptide may make the body build an immune response and kill tumor cells. PURPOSE: Randomized phase I trial to study the effectiveness of vaccine therapy in treating patients who have metastatic…
- Conditions
- Lung Cancer, Adult Soft Tissue Sarcoma, Colorectal Cancer, Bone Cancer
- Trial name
- NCT00020267
- Testing
- interleukin-2, MAGE-12 peptide vaccine, Montanide ISA-51
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Melanoma (Skin)
Nitrocamptothecin in Treating Patients With Metastatic Melanoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients who have…
- Trial name
- NCT00005875
- Testing
- rubitecan
- Where
- United States
- Sponsor
- Astex Pharmaceuticals, Inc.
Melanoma, Skin Neoplasms
Imatinib Mesylate in Treating Patients With Metastatic Melanoma
RATIONALE: Imatinib mesylate may interfere with the growth of tumor cells and may be an effective treatment for metastatic melanoma.
- Trial name
- NCT00027586
- Testing
- Imatinib mesylate (STI571)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- M.D. Anderson Cancer Center
Intraocular Melanoma, Melanoma (Skin)
Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma
RATIONALE: Biological therapies, such as MDX-010, work in different ways to stimulate the immune system and stop tumor cells from growing. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells.
- Trial name
- NCT00058279
- Testing
- aldesleukin, ipilimumab
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Recurrent Cutaneous Melanoma, Recurrent Lip and Oral Cavity Carcinoma
Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
This phase I trial studies the side effects and best dose of cord blood-derived expanded allogeneic natural killer cells (donor natural killer [NK] cells) and how well they work when given together with cyclophosphamide and…
- Conditions
- Recurrent Cutaneous Melanoma, Recurrent Lip and Oral Cavity Carcinoma, Recurrent Malignant Endocrine Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm
- Trial name
- NCT03420963
- Testing
- Cord Blood-derived Expanded Allogeneic Natural Killer Cells, Cyclophosphamide, Etoposide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- M.D. Anderson Cancer Center
Intraocular Melanoma, Melanoma (Skin)
Dendritic Cell Vaccination During Lymphoid Reconstruction
This is a randomized, controlled, multicenter, dose-escalation study of fludarabine. Patients are randomized to 1 of 2 treatment arms.
- Trial name
- NCT00313508
- Testing
- Autologous Dendritic Cells (DC), Fludarabine, Autologous Lymphocyte Infusion (ALI)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Melanoma (Skin)
Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: This randomized phase II trial is studying immunization using two different gp100 protein vaccines to compare how well they work in…
- Trial name
- NCT00072085
- Testing
- aldesleukin, gp100 antigen, incomplete Freund's adjuvant
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Cancer, Breast Cancer
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
This Phase 1/2 study evaluates the safety, feasibility, and preliminary anti-tumor activity of allogeneic donor-derived CAR-NK cells in participants with advanced solid tumors.
- Conditions
- Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (Locally Advanced or Metastatic)
- Trial name
- SELECT-CAR-NK (NCT07410494)
- Testing
- EB-SELECT Single-Target CAR-NK Cells, Dual-Target Antigen-Selected CAR-NK
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Essen Biotech
Melanoma
Impact of Excision Margins on Survival and Recurrence Rate in Patients With Thick Melanoma (>2mm)
Objective: To investigated the impact of the excision of melanoma 2mm≤ in thickness with 1cm surgical margins on survival of the patients compared with 2 cm surgical margins.
- Trial name
- NCT02088762
- Testing
- surgical excision
- Where
- Switzerland
- Volunteers
- 325 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Melanoma
Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma
The purpose of this study is to determine whether nivolumab is better than ipilimumab to prevent recurrence of melanoma.
- Trial name
- CheckMate 238 (NCT02388906)
- Testing
- Ipilimumab, Nivolumab
- Where
- 136 sites in United States, Argentina and 23 more
- Volunteers
- 906 people
- Sponsor
- Bristol-Myers Squibb
Pediatric Solid Tumor, Germ Cell Tumor
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
This is a phase I, open-label, non-randomized study that will enroll pediatric and young adult research participants with relapsed or refractory non-CNS solid tumors to evaluate the safety, feasibility, and efficacy of…
- Conditions
- Pediatric Solid Tumor, Germ Cell Tumor, Retinoblastoma, Hepatoblastoma
- Trial name
- NCT04483778
- Testing
- second generation 4-1BBζ B7H3-EGFRt-DHFR, second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG, Pembrolizumab
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Seattle Children's Hospital
Melanoma (Skin)
Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma
RATIONALE: Monoclonal antibodies, such as ipilimumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00357461
- Testing
- gp100:209-217(210M) peptide vaccine, gp100:280-288(288V) peptide vaccine, incomplete Freund's adjuvant
- Sponsor
- Bristol-Myers Squibb
Cancer
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
RATIONALE: Hepatic arterial infusion uses a catheter to deliver anticancer substances directly into the liver. Drugs used in chemotherapy, such as melphalan, work in different ways to stop tumor cells from dividing so they stop…
- Trial name
- NCT00096083
- Testing
- isolated perfusion, melphalan
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Delcath Systems Inc.
Melanoma (Skin)
Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma
RATIONALE: Vaccines made from a tumor antigen gene may make the body build an immune response to kill tumor cells. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood…
- Trial name
- NCT00002952
- Testing
- MART-1 antigen, recombinant MAGE-3.1 antigen, recombinant interleukin-12
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Chicago
Neuroblastoma, Rhabdomyosarcoma
Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
The purpose of this study is to find the safe dose of nab-paclitaxel in children with solid tumors, and to see if it works to treat these solid tumors in children and young adults (in Phase 1 ≤ 18 years old and in Phase 2 ≤ 24…
- Conditions
- Neuroblastoma, Rhabdomyosarcoma, Ewing's Sarcoma, Ewing's Tumor
- Trial name
- NCT01962103
- Testing
- nab-paclitaxel
- Where
- 20 sites in United States, Canada and 5 more
- Volunteers
- 107 people
- Sponsor
- Celgene
Melanoma (Skin)
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Metastatic Melanoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies use different ways to stimulate the immune system and stop cancer cell from growing.
- Trial name
- NCT00004141
- Testing
- Cisplatin, dacarbazine, Granulocyte-macrophage colony-stimulating factor
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Chicago